| HRA004909
(Controlled Access)
|
A total of 269 breast cancer patients receiving anthracycline and taxane-based chemotherapy were prospectively enrolled. Expression profiling using a 457 cancer-related gene sequencing panel covering genes recurrently mutated in breast cancer was carried out on 243 formalin-fixed paraffin-embedded tumor biopsies samples before NAC from 243 patients. The unique personalized panel of 9 individual somatic mutation genes from the above model was used to detect and analyze ctDNA on 216 blood samples from 56 patients. Blood samples were collected at indicated time points including before chemotherapy initiation, after the 1st NAC and before the 2nd NAC cycle, during intermediate evaluation, and prior to surgery. In this study, we characterized the value of gene profile mutation and circulating tumor DNA (ctDNA) in combination with clinical characteristics in the prediction of pCR before surgery and investigated the prognostic prediction. The median follow-up time for survival analysis was 898 days. |
